Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2022 | Impact of ADCs on the treatment landscape of UC

Daniel Petrylak, MD, Yale Cancer Center, New Haven, CT, provides an overview of the impact of antibody-drug conjugates (ADCs) on the treatment landscape of patients with urothelial carcinoma, including the use of enfortumab vedotin. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.